Vertex Pharmaceuticals is relatively new to the type 1 diabetes space, and they are working hard to understand what it’s like for people to live with T1D so they can develop transformative therapies. They’re currently investigating and advancing cell therapies aimed at treating an underlying cause of type 1 – the absence of insulin-producing cells.
read more →
Dr. Ian Paterson, a medical practitioner at the University of Sheffield who lives with T1D, explains how the “honeymoon phase” that often occurs with type 1 can potentially be used to delay its full development, and why it’s important to preserve even a small number of functioning beta cells if you can.
read more →
Our international panel of diabetes experts discussed highlights from the ADA’s Scientific Sessions, and lead a Q&A on some of the most important advances in diabetes.
read more →
Our 14th Annual Diabetes Forum featured engaging and informative panel discussions from the world’s leading diabetes experts, and highlighted the latest developments in diabetes care from ADA’s Scientific Sessions.
read more →
A new drug recently got a breakthrough indication from the FDA to treat people at risk for getting T1D. What does that mean for the whole type 1 community?
read more →
Evidence-based hope is letting people know that things are different than they were even 20 years ago. We now know that that with well-managed type 1 or type 2 diabetes, the odds are good you’re going to live a long and healthy life.
read more →
TrialNet is an international network of leading academic institutions, physicians, scientists and healthcare teams dedicated to the prevention of type 1 diabetes. They offer risk screening for relatives of people with type 1 diabetes and innovative clinical studies to preserve insulin production.
read more →
It is now possible to manufacture insulin-producing cells in a lab, using multiple different techniques developed by a multitude of researchers. What does this mean for people living with type 1 diabetes, or who are insulin dependent?
read more →
